Surrozen, Inc.

SRZN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Operating Activities
Net Income $50.2M $-127.5M $-183.2M $-71.6M $39.7M $-27.0M $-28.0M $-1.4M
Depreciation & Amortization $51.0K $65.0K $45.0K $61.0K $137.0K $294.0K $322.0K $342.0K
Depreciation — — — — — — — —
Amortization — — — — — — — —
Stock-Based Compensation $2.9M $2.1M $1.0M $1.0M $994.0K $834.0K $900.0K $1.0M
Net Cash from Operating Activities $-7.4M $-12.5M $-5.8M $-9.0M $-6.1M $-9.3M $3.5M $-6.8M
Investing Activities
Capital Expenditures $19.0K $120.0K $59.0K $24.0K $18.0K $27.0K $19.0K $0
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $-19.0K $-120.0K $-59.0K $-24.0K $-18.0K $-27.0K $-19.0K $0
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $2.5M $30.3M $13.8M $9.0K $-5.1M $76.4M $91.0K $-1.0K
Net Change in Cash $-4.9M $17.7M $7.9M $-9.1M $-11.3M $67.1M $3.6M $-6.8M
Free Cash Flow $-7.4M $-12.6M $-5.9M $-9.1M $-6.1M $-9.3M $3.5M $-6.8M
← Newer Page 1 of 3 Older →